NanoViricides, Inc. (stock symbol: NNVC.OB) is working in the general field of Nanomedicine. This is a very diverse field and encompasses a wide range of materials and applications. Specifically, we are working in the area of targeted anti-viral therapeutics. Utilizing nanoscale materials and processes licensed from TheraCour Pharma, Inc., we are developing anti-viral drugs against a wide range range of human and animal viruses.

NanoViricides, Inc. is a nano-biopharmaceutical company whose business goals are to discover, develop and commercialize therapeutics (nanoviricides™) to advance the care of patients suffering from life-threatening viral infections.

NanoViricides, Inc. is a development stage company. The Company's novel nanoviricide™ class of drug candidates are designed to specifically attack enveloped virus particles and to dismantle them. The Company is developing drugs against a number of viral diseases including H5N1 bird flu, seasonal influenza, HIV, Epidemic Kerato-Conjunctivitis (EKC), hepatitis C, rabies, dengue fever, and Ebola virus, among others.